- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab, Atorvastatin, Placebo
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Indianapolis, Indiana + 8 more
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab (PF-04950615;RN316), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more
- Conditions
- Type II Diabetes Mellitus, Mixed Dyslipidemia
- Interventions
- fenofibrate 160 mg and placebo, simvastatin 20 mg and placebo, fenofibrate 160 mg and simvastatin 20 mg
- Drug
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Ogden, Utah • Salt Lake City, Utah
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- NK-104-CR, Placebo, Livalo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 45
- States / cities
- Beverly Hills, California • Chino, California • Lincoln, California + 42 more
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
- Interventions
- CTX310
- Drug
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 6 more
- Conditions
- Primary Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Evolocumab AMD, Evolocumab AI/pen
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Interventions
- Evolocumab, Placebo to Evolocumab
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 46
- States / cities
- Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- Mixed Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin, atorvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 37 more
- Conditions
- Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin, atorvastatin, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 96
- States / cities
- Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
- Conditions
- Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- Evolocumab, Standard of Care
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Interventions
- PPD10558, Atorvastatin, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 67
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 30
- States / cities
- Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more
- Conditions
- Hyperlipemia, Mixed, ASCVD
- Interventions
- Alert
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dyslipidemia
- Interventions
- LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 38
- States / cities
- Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab (PF-04950615; RN316), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 155
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab (PF-04950615; RN316), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 108
- States / cities
- Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
- Conditions
- Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
- Interventions
- Niacin Extended Release/Lovastatin
- Drug
- Lead sponsor
- In His Image
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Hypertension, Hyperglycemia, Dyslipidemia, Metabolic Syndrome, Obesity &Amp; Overweight, Diabetes, Hyperlipidemia, Emergency Medicine
- Interventions
- Composite intervention to address MetS
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Interventions
- Vupanorsen, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 59
- States / cities
- Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
- Conditions
- Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
- Interventions
- LY3561774, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey